تداخلات دوكسيبين

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (نشرة إبراتروبيوم، التداخلات الدوائية)

Antidepressants: tricyclic antidepressants ↑ tricyclic antidepressants Coadministration with REYATAZ has the potential to produce serious and/or life-threatening adverse events and has not been studied. (نشرة أتازانافير، التداخلات الدوائية)

Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (نشرة دوكسيبين، موانع الاستعمال)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (نشرة أزيلاستين وفلوتيكازون، التحذيرات والاحتياطات)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (نشرة إسزوبيكلون، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (نشرة إسيتالوبرام، التحذيرات والاحتياطات)

Avoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs. (نشرة أكليدينيوم، التداخلات الدوائية)

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (نشرة ألبرازولام، التحذيرات والاحتياطات)

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (نشرة البلادونا والأفيون، تحذير مؤطر)

…Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which… (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، موانع الاستعمال)

Do not use with alcohol. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs and MAO inhibitors [see Warnings and Precautions (5.7) ]. (نشرة إليتريبتان، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة أمفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (نشرة أمفيتامين وديكستروأمفيتامين، التحذيرات والاحتياطات)

Anyone considering the use of amoxapine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة أموكسابين، تحذير مؤطر)

Anyone considering the use of amitriptyline hydrochloride tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة أميتريبتيلين، تحذير مؤطر)

Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. (نشرة أوكسيبات الصوديوم، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة أوكسيكودون، تحذير مؤطر)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (نشرة أوكسيكودون وباراسيتامول، تحذير مؤطر)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة أوكسيمورفون، تحذير مؤطر)

If concomitant use of olanzapine and fluoxetine capsules with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 5.6 ) (نشرة أولانزابين وفلوكسيتين، التحذيرات والاحتياطات)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (نشرة أولوباتادين، التحذيرات والاحتياطات)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (نشرة أولوباتادين وموميتازون، التحذيرات والاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة أوليسيريدين، تحذير مؤطر)

Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs. (نشرة أوميكليدينيوم، التداخلات الدوائية)

Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs. (نشرة أوميكليدينيوم وفيلانتيرول، التداخلات الدوائية)

S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (نشرة أوندانسيترون، التحذيرات والاحتياطات)

Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (نشرة دوكسيبين، موانع الاستعمال)

Anyone considering the use of imipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة إيميبرامين، تحذير مؤطر)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة باراسيتامول وكودايين، تحذير مؤطر)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة باروكسيتين، التحذيرات والاحتياطات)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Anyone considering the use of protriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة بروتريبتيلين، تحذير مؤطر)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (نشرة بروميثازين وكودايين، تحذير مؤطر)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (نشرة بنتازوسين ونالوكسون، تحذير مؤطر)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوبرينورفين، تحذير مؤطر)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتورفانول، تحذير مؤطر)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (نشرة بوسبيرون، التحذيرات)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بيثيدين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة تابنتادول، تحذير مؤطر)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (نشرة ترازودون، التحذيرات والاحتياطات)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ترامادول، تحذير مؤطر)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ترامادول وباراسيتامول، تحذير مؤطر)

Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (نشرة دوكسيبين، موانع الاستعمال)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (نشرة تريازولام، التحذيرات والاحتياطات)

Anyone considering the use of trimipramine capsules or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة تريميبرامين، تحذير مؤطر)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (نشرة تيوتروبيوم، التداخلات الدوائية)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (نشرة دارونافير، موانع الاستعمال)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated in patients receiving certain co-administered drugs for which altered plasma… (نشرة دارونافير وكوبيسيستات، موانع الاستعمال)

…Pharmacology (12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval… (نشرة درونيدارون، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (نشرة دولوكسيتين، التحذيرات والاحتياطات)

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ديسفينلافاكسين، التحذيرات والاحتياطات)

Anyone considering the use of NORPRAMIN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة ديسيبرامين، تحذير مؤطر)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (نشرة ديفينوكسيلات وأتروبين، موانع الاستعمال)

Usage of MOTOFEN ® in recommended doses is not likely to cause prominent anticholinergic side effects, but MOTOFEN ® should be avoided in patients in whom anticholinergic drugs are contraindicated. (نشرة ديفينوكسين وأتروبين، التحذيرات)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

Serotonin syndrome: Use of NUEDEXTA with selective serotonin reuptake inhibitor (SSRIs) or tricyclic antidepressants increases the risk. (نشرة ديكستروميثورفان وكينيدين، التحذيرات والاحتياطات)

Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (نشرة دوكسيبين، موانع الاستعمال)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (نشرة ريتونافير، تحذير مؤطر)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (نشرة ريفاستيغمين، التداخلات الدوائية)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ريميفنتانيل، تحذير مؤطر)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (نشرة زاليبلون، التحذيرات)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (نشرة زولبيديم، التحذيرات والاحتياطات)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة زيبراسيدون، التحذيرات والاحتياطات)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (نشرة سترات البوتاسيوم، موانع الاستعمال)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (نشرة سوماتريبتان، التداخلات الدوائية)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (نشرة سوماتريبتان ونابروكسين، التداخلات الدوائية)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (نشرة سيبروفلوكساسين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيتالوبرام، التحذيرات والاحتياطات)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (نشرة سيتريزين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs. (نشرة سيكلوبنزابرين، موانع الاستعمال)

Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (نشرة دوكسيبين، موانع الاستعمال)

Serotonin syndrome has been reported with granisetron products, alone but particularly with concomitant use of serotonergic drugs. (نشرة غرانيسيترون، التحذيرات والاحتياطات)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (نشرة غلوكاغون، التداخلات الدوائية)

• Other Conditions Exacerbated by Anticholinergic Adverse Reactions : Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc. (نشرة غليكوبيرولات، التحذيرات والاحتياطات)

Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during combined use of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [ see Warnings and Precautions (5.7) ]. (نشرة فروفاتريبتان، التداخلات الدوائية)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فلوفوكسامين، تحذير مؤطر)

If concomitant use of PROZAC with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 5.2 ) (نشرة فلوكسيتين، التحذيرات والاحتياطات)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (نشرة فلومازينيل، تحذير مؤطر)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة فنتانيل، تحذير مؤطر)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (نشرة فورتيوكسيتين، التحذيرات والاحتياطات)

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (نشرة فوسامبرينافير، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة فيلازودون، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (نشرة دوكسيبين، موانع الاستعمال)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (نشرة كاربامازيبين، موانع الاستعمال)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (نشرة كاربينوكسامين، التحذيرات والاحتياطات)

When possible, avoid concomitant use, with other anticholinergic medications because the risk for anticholinergic toxicity or severe gastrointestinal adverse reactions is increased [see Warnings and Precautions ( 5.7 ), Drug Interactions ( 7.1 )]. (نشرة كلوزابين، التحذيرات والاحتياطات)

Anyone considering the use of clomipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة كلوميبرامين، تحذير مؤطر)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (نشرة كلونيدين، التحذيرات والاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة كودايين، تحذير مؤطر)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (نشرة كيتامين، التداخلات الدوائية)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (نشرة كيتوكونازول، موانع الاستعمال)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (نشرة كينيدين، موانع الاستعمال)

…Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations… (نشرة لوبينافير وريتونافير، موانع الاستعمال)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (نشرة لورازيبام، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ليسديكسامفيتامين، التحذيرات والاحتياطات)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ليفورفانول، تحذير مؤطر)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (نشرة ليفوسيتريزين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (نشرة دوكسيبين، موانع الاستعمال)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة مورفين، تحذير مؤطر)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (نشرة ميتاكسالون، التحذيرات والاحتياطات)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (نشرة ميتوكلوبراميد، التحذيرات والاحتياطات)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (نشرة ميثادون، تحذير مؤطر)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ميثامفيتامين، التحذيرات والاحتياطات)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (نشرة ميدازولام، تحذير مؤطر)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (نشرة ميرتازابين، التحذيرات والاحتياطات)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ميلناسيبران، التحذيرات والاحتياطات)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (نشرة ناراتريبتان، التداخلات الدوائية)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة نالبوفين، تحذير مؤطر)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (نشرة نالميفين، التحذيرات والاحتياطات)

الجمع بين نبتة سانت جون ومضادات الاكتئاب والأدوية السيروتونينية الأخرى يزيد خطر متلازمة السيروتونين. (NCCIH, St. John's Wort)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

…(selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin • Vasopressin receptor antagonists: tolvaptan ➢ Drugs that… (نشرة نيرماتريلفير وريتونافير، موانع الاستعمال)

Anyone considering the use of nefazodone hydrochloride tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نيفازودون، تحذير مؤطر)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (نشرة هيدروكسيزين، الاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة هيدروكودون، تحذير مؤطر)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (نشرة هيدروكودون وإيبوبروفين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة هيدروكودون وباراسيتامول، تحذير مؤطر)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (نشرة هيدروكودون وكلورفينيرامين، تحذير مؤطر)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (نشرة هيدروكودون وهوماتروبين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (نشرة هيدرومورفون، تحذير مؤطر)

Caution is, therefore, advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution with other drugs having anticholinergic properties. β-adrenergic agents Caution is advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution and other sympathomimetic agents due to the increased risk… (نشرة إبراتروبيوم وسالبوتامول، التداخلات الدوائية)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (نشرة أدرينالين، التداخلات الدوائية)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة أرتيكايين وأدرينالين، التداخلات الدوائية)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (نشرة أرفورموتيرول، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (نشرة ألوبيورينول، التحذيرات والاحتياطات)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (نشرة أمينوفيلين، التداخلات الدوائية)

Table 5: Amiodarone Drug Interactions Concomitant Drug Class/Name Examples Clinical Comment QT Prolonging Drugs class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents Increased risk of Torsade de Pointes. (نشرة أميودارون، التداخلات الدوائية)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (نشرة إنكوبوتولينوم توكسين A، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Oxybutynin chloride extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony. (نشرة أوكسيبوتينين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (نشرة أونابوتولينوم توكسين A، التداخلات الدوائية)

SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions. (نشرة إيتراكونازول، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (نشرة إيزوبرينالين، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Antidepressant: Bupropion Sertraline ↓ bupropion * ↓ sertraline * Increases in bupropion dosage should be guided by clinical response. (نشرة إيفافيرينز، التداخلات الدوائية)

Antidepressants: Bupropion ↓ bupropion Increases in bupropion dosage should be guided by clinical response. (نشرة إيفافيرينز ولاميفودين وتينوفوفير، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (نشرة بروكاييناميد، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة بريلوكايين وأدرينالين، التداخلات الدوائية)

Use with CNS depressants may result in an additive or potentiating effect. (نشرة بريمونيدين، التداخلات الدوائية)

Use with CNS depressants may result in an additive or potentiating effect. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Amphetamines may enhance the effects of tricyclic antidepressants. (نشرة بنزفيتامين، التداخلات الدوائية)

…following conditions can also increase the risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit… (نشرة بوبروبيون، التحذيرات والاحتياطات)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة بوبيفاكايين وأدرينالين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة بوديزونيد وفورموتيرول، التداخلات الدوائية)

Concomitant Use with Midazolam : Noxafil can prolong hypnotic/sedative effects. (نشرة بوساكونازول، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (نشرة بيريدوستيغمين، التحذيرات والاحتياطات)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (نشرة بيلوكاربين، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. (نشرة بينازيبريل وهيدروكلوروثيازيد، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Trospium chloride extended-release capsules, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. (نشرة تروسبيوم، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (نشرة تريميثوبنزاميد، التحذيرات والاحتياطات)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (نشرة توريميفين، التداخلات الدوائية)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (نشرة توكسين البوتولينوم من النمط A، التداخلات الدوائية)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (نشرة تيربوتالين، الاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (نشرة ثيوفيلين، التداخلات الدوائية)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Darifenacin extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as severe constipation, ulcerative colitis, and myasthenia gravis. (نشرة داريفيناسين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Other Drugs that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide,… (نشرة ديسموبريسين، التداخلات الدوائية)

Anticholinergic agents: may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs (7) (نشرة ديسيكلومين، التداخلات الدوائية)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (نشرة ديوتيترابينازين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Drugs transported by P-gp (e.g., digoxin), or drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants) may need reduced doses when used with ASPRUZYO Sprinkle. (نشرة رانولازين، التداخلات الدوائية)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (نشرة ريزاتريبتان، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (نشرة ريفابنتين، التداخلات الدوائية)

…Selective 5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25… (نشرة ريفامبيسين، التداخلات الدوائية)

The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (نشرة زولميتريبتان، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة سالبوتامول، التداخلات الدوائية)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة سالميتيرول، التداخلات الدوائية)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (نشرة سكسينيل كولين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (نشرة سلفاميثوكسازول وتريميثوبريم، التداخلات الدوائية)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (نشرة سوغاماديكس، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Urinary Retention The use of Solifenacin succinate tablets, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction including patients with urinary retention, may result in further urinary retention and kidney injury. (نشرة سوليفيناسين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Cimetidine: Increases exposure to doxepin. (نشرة دوكسيبين، التداخلات الدوائية)

Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology ( 12.3 )] . (نشرة سيناكالسيت، التداخلات الدوائية)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (نشرة غيفيتينيب، التداخلات الدوائية)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (نشرة فازوبريسين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (نشرة فالبينازين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (نشرة فورموتيرول، التداخلات الدوائية)

Eszopiclone (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased which may Increase the Sedative Effect of Eszopiclone Dose reduction of eszopiclone is recommended. (نشرة فوريكونازول، التداخلات الدوائية)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (نشرة فوسفومايسين، التداخلات الدوائية)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

…prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic antidepressants, and certain macrolides and fluoroquinolones. (نشرة فوسكارنت، التداخلات الدوائية)

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. (نشرة فيبيغرون، التحذيرات والاحتياطات)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (نشرة فيزوستيغمين، التحذيرات والاحتياطات)

Urinary Retention in Adult Patients With Bladder Outlet Obstruction The use of Toviaz, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction, including patients with urinary retention, may result in further urinary retention and kidney injury. (نشرة فيسوتيرودين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (نشرة فينيليفرين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (نشرة كاربيدوبا، التحذيرات)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة كلوروبروكايين، الاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (نشرة كوكايين، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة ليدوكايين، التداخلات الدوائية)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة ليدوكايين وأدرينالين، التحذيرات والاحتياطات)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (نشرة ليفوثيروكسين، التداخلات الدوائية)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (نشرة ليفوسالبوتامول، التداخلات الدوائية)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (نشرة ليوثيرونين، التداخلات الدوائية)

In individuals deficient in the CYP2D6 enzyme, the levels of CYP2D6 substrates which have ancillary routes of elimination through CYP2C19, such as tricyclic antidepressants and selective serotonin reuptake inhibitors, may be increased by co-administration of PROVIGIL. (نشرة مودافينيل، التداخلات الدوائية)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (نشرة موكسيفلوكساسين، التحذيرات والاحتياطات)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (نشرة ميبيفاكايين، التحذيرات)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (نشرة ميتيروسين، التداخلات الدوائية)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (نشرة ميثسكوبولامين، التداخلات الدوائية)

Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

• Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder : Administer with caution in these patients because of risk of urinary retention. (نشرة ميرابيغرون، التحذيرات والاحتياطات)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (نشرة ميفلوكين، التداخلات الدوائية)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

…(sulfonylureas and meglitinides) that may cause hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may… (نشرة نالتريكسون وبوبروبيون، التحذيرات والاحتياطات)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (نشرة نالوكسون، التحذيرات والاحتياطات)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (نشرة نيوستيغمين، التحذيرات والاحتياطات)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (نشرة دوكسيبين، التحذيرات والاحتياطات)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (نشرة إيبويتين ألفا، التحذيرات والاحتياطات)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (نشرة برازوسين، التداخلات الدوائية)

Such drugs may include many antiarrhythmics, some phenothiazines, tricyclic antidepressants, and oral macrolides. (نشرة بروبافينون، التحذيرات والاحتياطات)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (نشرة بروبرانولول، التداخلات الدوائية)

When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. (نشرة بنزتروبين، التحذيرات)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (نشرة تولكابون، الاحتياطات)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (نشرة تيربينافين، التداخلات الدوائية)

Such drugs include phenothiazines, cisapride, bepridil, tricyclic antidepressants, certain oral macrolides, and certain fluoroquinolones. (نشرة دوفيتيليد، التحذيرات)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (نشرة دوكسابرام، التحذيرات)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (نشرة دونيبيزيل، التداخلات الدوائية)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (نشرة سيفيميلين، التداخلات الدوائية)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (نشرة غالانتامين، التداخلات الدوائية)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (نشرة فينترمين، التحذيرات والاحتياطات)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (نشرة لوفاستاتين، التحذيرات)

NAMZARIC may interfere with anticholinergic medications. (نشرة ميمانتين ودونيبيزيل، التداخلات الدوائية)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (نشرة إنتاكابون، الاحتياطات)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA 7.4 Drugs without Clinically Significant Interactions with SUNLENCA Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with:… (نشرة ليناكابافير، التداخلات الدوائية)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (نشرة مونتيلوكاست، التداخلات الدوائية)